Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrolife ABCHIX:VITRS 66 Cash Ratio is 1.36 as of Jun. 2026, which is 18% below its 10-year median of 1.66. GuruFocus rates CHIX:VITRS with a GF Score™ of 66/100 and a GF Value™ of kr179.48 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 836 Medical Devices & Instruments companies, Vitrolife AB ranks better than 59.45% on this metric.
Vitrolife AB has a Cash Ratio of 1.36. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Vitrolife AB's Cash Ratio or its related term are showing as below:
CHIX:VITRs'
s Cash Ratio Range Over the Past 10 Years
Min: 0.59 Med: 1.66 Max: 19.4
Current: 1.36
During the past 13 years, Vitrolife AB's highest Cash Ratio was 19.40. The lowest was 0.59. And the median was 1.66.
CHIX:VITRs's Cash Ratio is ranked better than 59.45% of 836
companies
in the Medical Devices & Instruments industry
Industry Median: 0.95
vs CHIX:VITRs: 1.36
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Vitrolife AB Cash Ratio Related Terms
Vitrolife AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VITRS vs ABT, SYK, MDT: Cash Ratio Comparison
For the Medical Devices subindustry, Vitrolife AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (CHIX:VITRS) has a Cash Ratio of 1.36 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vitrolife AB and its competitors. This is 18% below median its historical median of 1.66. Over the past decade, Vitrolife AB's Cash Ratio has ranged from 0.59 to 19.40. According to the industry distribution chart, Vitrolife AB ranks #339 out of 836 companies in the Medical Devices & Instruments industry, placing it in the top 40.6%.
Is Vitrolife AB's Cash Ratio too high?
Vitrolife AB's current Cash Ratio of 1.36 is 18% below median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 19.40. The Medical Devices & Instruments industry median Cash Ratio is 0.95. Vitrolife AB's value of 1.36 is 43.2% above this industry median. Based on the distribution chart, Vitrolife AB ranks #339 out of 836 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Vitrolife AB has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #339 out of 836 companies for Cash Ratio. This puts Vitrolife AB in the upper half of its industry. The industry median Cash Ratio is 0.95. Vitrolife AB's value of 1.36 is 43.2% above this benchmark. Historically, Vitrolife AB's own Cash Ratio has ranged from 0.59 to 19.40 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 0.95, Vitrolife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.95, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current Cash Ratio of 1.36 is 43.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current Cash Ratio is 1.36, which is 18% below median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr179.48, compared to a current price of kr86.38 — trading 51.9% below its estimated fair value. The current Cash Ratio is 1.36, which is 18% below median its 10-year median of 1.66 and 43.2% above the Medical Devices & Instruments industry median of 0.95. Vitrolife AB's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Cash Ratio is 1.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr86.38 is trading 51.9% below its estimated GF Value™ of kr179.48.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for CHIX:VITRS:
Cash Ratio: 1.36 (18% below median its 10-year median of 1.66)
GF Value™: kr179.48 vs. price of kr86.38 (51.9% below fair value)
Industry Position: 43.2% above the Medical Devices & Instruments median (#339 of 836)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
66GF Score
Get the complete analysis for CHIX:VITRS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
